Glenmark Pharmaceuticals has launched nicotine replacement therapy product ‘Kwitz’ that helps smokers quit smoking. Kwitz nicotine gum will be available in two variants of 2 mg as an OTC product and 4mg as prescription product. While Kwitz 2 mg is for those smoking less than 20 cigarettes per day, Kwitz 4 mg is meant for smokers consuming more than 20 cigarettes per day.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
